Last updated: April 25, 2026
Who Supplies Haloperidol for Pharmaceutical Manufacturing and Finished Dosage Markets?
Haloperidol is a widely used antipsychotic with global supply anchored by (1) API producers of haloperidol (base and/or intermediate-specific routes), (2) salt-form/finished-dose manufacturers (commonly oral tablets and long-acting injectable presentations), and (3) contract manufacturers for generics and branded equivalents. The supplier landscape splits by API vs finished dosage and by formulation type (oral solids vs long-acting depot).
What supplier categories exist for haloperidol?
| Supplier type |
What they provide |
Typical downstream customer |
Common product forms |
| API manufacturer |
Haloperidol active pharmaceutical ingredient (API) |
Generic manufacturers, brand OEMs, contract packagers |
Haloperidol API (base), sometimes variant specs by grade |
| Finished dosage manufacturer |
Registered finished dosage form (FDF) using haloperidol API |
Marketers, wholesalers, national procurement |
Oral tablets, oral drops/syrup (market-dependent) |
| Depot/LAI manufacturer |
Long-acting injectable manufacturing (where applicable in a market) |
Hospital supply chains, centralized procurement |
Long-acting formulations (market-dependent) |
| Contract manufacturing organization (CMO) |
Packaging, secondary processing, tech transfer execution under quality agreements |
Generics and labelers |
Tablets/capsules fill-finish, packaging, sometimes analytics |
Because the market is mature, most procurement decisions track to regulatory registrations (where the label exists), GMP status, and supply continuity, with procurement handled through qualified vendor lists and long-term supply contracts.
Who supplies haloperidol as the API?
Haloperidol API sourcing is dominated by large specialty generics and Indian and Chinese API manufacturers with established sterile and non-sterile capabilities depending on the presentation. Supplier lists in practice come from three proof points:
- FDA Orange Book listings for haloperidol-containing products (driven by FDF manufacturers, which indirectly reveals supply chain via ANDA registrants).
- Regulatory dossiers and inspections (GMP manufacturing sites disclosed in regulatory filings).
- DMF/CEP-supported API supply channels used by FDF applicants.
API supply model used in haloperidol generics
Most haloperidol generic product makers source API from a small set of repeat-qualified API sites, then run their own formulation and packaging under local registration. This concentrates supplier dependency for haloperidol API at the level of a handful of qualified API producers per region.
Procurement signal that points to API supplier concentration: haloperidol tablets and related oral products are frequently made by multiple labelers using the same core API and comparable dissolution/assay specs across ANDA products.
Who supplies haloperidol finished dosage products?
Finished-dose suppliers are visible via:
- ANDA registrants and NDA holders for haloperidol oral products (tablets and other oral forms depending on country).
- Marketing authorization holders in each jurisdiction.
- Wholesaler product sourcing through tendered FDFs.
Finished dosage procurement reality
In most markets, the finished-dose supplier is the direct counterparty for procurement, not the API producer. Contracting typically runs through:
- local distributors,
- tendered generics,
- and label holders with established pharmacovigilance systems.
For business decisions, the “supplier” typically means the market authorization holder / finished-dose manufacturer for the specific presentation and strength.
Which haloperidol formulations control supplier selection?
Supplier qualification changes materially by presentation:
Oral tablets and oral formulations
- Primary supplier qualification drivers: API assay/impurities, tablet formulation process capability, dissolution profile, and packaging integrity.
- Supply chain complexity: lower than sterile/LAI.
Long-acting injectable (depot) presentations
- Primary supplier qualification drivers: sterile manufacturing capabilities, depot suspension uniformity, syringe filling standards, and container closure system.
- Supply chain complexity: higher, with narrower manufacturing capacity.
What supplier set should procurement teams use for haloperidol?
Procurement teams typically lock vendor selection into a qualified vendor list (QVL) for each of the following:
- Haloperidol API grade/spec version required by the product registration.
- Tablet or injectable manufacturing site and validated process.
- Packaging format (blister, bottle) and labeling compliance for local market.
For a mature molecule like haloperidol, the operational best practice is vendor consolidation: qualify a small number of API and FDF sources per region to reduce lead time and ensure continuity.
How to identify the “real suppliers” by evidence in public regulatory records
If the goal is to produce a concrete vendor list (company name and site), the evidence comes from:
- Regulatory registration ownership (who holds/registered the product).
- Site disclosures (manufacturing location tied to registration).
- API sourcing disclosures where present (DMF/CEP or publicly visible dossier references).
Without a targeted jurisdiction and product form, any “supplier list” risks mixing:
- API producers with FDF manufacturers,
- and different formulations (oral vs depot),
which breaks direct procurement relevance.
Key Takeaways
- Haloperidol supply splits into API manufacturers, finished-dose manufacturers, and depot/LAI capable manufacturers (where applicable by market).
- In practice, “supplier” usually means the finished-dose manufacturer/marketing authorization holder for the exact presentation being purchased.
- Mature haloperidol markets concentrate sourcing through a small set of repeat-qualified API and FDF sites, so supplier selection should be executed via QVL and registration-linked site qualification.
FAQs
1) Are haloperidol API suppliers the same as finished-dose manufacturers?
No. API producers supply haloperidol to multiple finished-dose manufacturers, while finished-dose firms control formulation, packaging, and the local regulatory registration.
2) Do suppliers differ for oral versus long-acting injectable haloperidol?
Yes. Oral products rely on non-sterile formulation and packaging, while depot/LAI manufacturing requires sterile and depot-specific process capabilities.
3) Where can haloperidol supplier evidence be verified?
Via regulatory product listings that identify ANDA/NDA holders and manufacturing sites, supplemented by dossier-driven API qualification channels (DMF/CEP when disclosed in filings).
4) How do procurement teams reduce supply risk for haloperidol?
By consolidating to a limited number of qualified sources per region for both API and finished dosage, then securing contracts tied to site capacity and quality agreements.
5) What determines which supplier wins tenders for haloperidol?
Regulatory standing for the specific presentation and strength, GMP compliance of the manufacturing site, supply continuity, pricing, and tender logistics (pack size and distribution terms).
References
[1] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA European Medicines Agency. European Public Assessment Reports (EPAR) database. https://www.ema.europa.eu/en/medicines
[3] WHO prequalification programme (when applicable for supplier qualification in procurement). World Health Organization. https://extranet.who.int/pqweb/
